US Full Prescribing Information Patient Information Important Safety Information Consumer Site
About Onglyza™Diabetes Conferences - Calendar of Upcoming Events Onglyza™ Value Card Program
The Onglyza™ Value Card Program

It's Easy
Accessing the Onglyza Value Card is quick and easy for you and your patient.
All you have to do is:
  1. Obtain a supply of Onglyza Value Cards for your eligible patients
    by contacting your Onglyza sales representative.
  2. Ask patients to activate their Onglyza Value Card by calling 1-866-784-3435
    or going online.
That's it! No repeat card presentations to your patients' pharmacy of record or calls to your office are necessary.‡
‡A change in pharmacies would require that the patient re-present the Value Card.
Onglyza™ Value Card
Onglyza Value Card Program Details and Eligibility
  • Eligible patients with commercial prescription coverage whose copay (out-of-pocket expense) for
    a 30-day supply of Onglyza (saxagliptin) is more than $30 may receive up to $50 in savings. Savings not applicable to out-of-pocket expenses of $30 or less.
  • Eligible patients without commercial prescription coverage (cash-paying patients) can receive up to $50 in savings per 30-day supply for Onglyza.
  • Any necessary step-edits or prior authorizations required by the insurance plan still apply.
  • Patients are not eligible if prescriptions are paid in part or full by any state or federally funded programs, including but not limited to Medicare or Medicaid, Medigap, VA, DOD, or Tricare. Offer not valid in Massachusetts or where prohibited by law, taxed or restricted. The Onglyza Value Card is not an insurance card.
  • First card use must take place by 8/31/10. Limited to 1 card per patient. This card is good for savings on up to twelve 30-day supplies. Card expires 15 months from date of activation.
  • The Onglyza Value Card is accepted at participating retail pharmacies and may also be used for mail order.
  • The Onglyza Value Card must be presented along with a valid prescription for Onglyza at the time of purchase.
  • Bristol-Myers Squibb and AstraZeneca reserve the right to modify or discontinue this offer at any time.
IMPORTANT INFORMATION ABOUT ONGLYZA (saxagliptin)
Indication and Important Limitations of Use
ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
ONGLYZA has not been studied in combination with insulin.
Important Safety Information
  • Use with Medications Known to Cause Hypoglycemia: Insulin secretagogues, such as sulfonylureas, cause hypoglycemia. Therefore, a lower dose of the insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with ONGLYZA
  • Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug
Most common adverse reactions (regardless of investigator assessment of causality) reported in ≥5% of patients treated with ONGLYZA and more commonly than in patients treated with control were upper respiratory tract infection (7.7%, 7.6%), headache (7.5%, 5.2%), nasopharyngitis (6.9%, 4.0%) and urinary tract infection (6.8%, 6.1%). When used as add-on combination therapy with a thiazolidinedione, the incidence of peripheral edema for ONGLYZA 2.5 mg, 5 mg, and placebo was 3.1%, 8.1% and 4.3%, respectively.
Drug Interactions: Because ketoconazole, a strong CYP3A4/5 inhibitor, increased saxagliptin exposure, the dose of ONGLYZA should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin).
Patients with Renal Impairment: The dose of ONGLYZA is 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease requiring hemodialysis (creatinine clearance [CrCl] ≤50 mL/min). ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis. Assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter.
Pregnant and Nursing Women: There are no adequate and well-controlled studies in pregnant women. ONGLYZA, like other antidiabetic medications, should be used during pregnancy only if clearly needed. It is not known whether saxagliptin is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when ONGLYZA is administered to a nursing woman.
Pediatric Patients: Safety and effectiveness of ONGLYZA in pediatric patients have not been established.
Please see US Full Prescribing Information for Onglyza (saxagliptin).